WallStreetZenWallStreetZen

NASDAQ: CALT
Calliditas Therapeutics Ab Earnings & Revenue

CALT past revenue growth

How has CALT's revenue growth performed historically?
Company
214.74%
Industry
169.3%
Market
17.86%
CALT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CALT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CALT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CALT earnings and revenue history

Current Revenue
$105.9M
Current Earnings
-$26.9M
Current Profit Margin
-25.4%

CALT Return on Equity

Current Company
-47.7%
Current Industry
1.3%
Current Market
-0.3%
CALT's Return on Equity (-47.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CALT announces earnings.

CALT Return on Assets

Current Company
-18.5%
Current Industry
-1.5%
CALT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CALT Return on Capital Employed

Current Company
-18.25%
Current Industry
11.8%
CALT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CALT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CALT$105.20MN/A-$26.74M+271.10%N/A
MLYS$0.00-$71.90M-$71.90MN/AN/A
PHAT$682.00k-$159.05M-$201.59MN/AN/A
NGNE$0.00-$32.35M-$36.32M-100.00%N/A
OABI$34.16M-$44.87M-$50.62M+16.86%N/A

CALT earnings dates

Next earnings date
May 7, 2024

Calliditas Therapeutics Ab Earnings & Revenue FAQ

What were CALT's earnings last quarter?

On Invalid Date, Calliditas Therapeutics Ab (NASDAQ: CALT) reported Q2 2023 earnings per share (EPS) of -$0.32, up 55.63% year over year. Total Calliditas Therapeutics Ab earnings for the quarter were -$8.47 million. In the same quarter last year, Calliditas Therapeutics Ab's earnings per share (EPS) was -$0.71.

If you're new to stock investing, here's how to buy Calliditas Therapeutics Ab stock.

What was CALT's earnings growth in the past year?

As of Q1 2024, Calliditas Therapeutics Ab's earnings has grown year over year. Calliditas Therapeutics Ab's earnings in the past year totalled -$26.74 million.

What is CALT's earnings date?

Calliditas Therapeutics Ab's earnings date is Invalid Date. Add CALT to your watchlist to be reminded of CALT's next earnings announcement.

What was CALT's revenue last quarter?

On Invalid Date, Calliditas Therapeutics Ab (NASDAQ: CALT) reported Q2 2023 revenue of $24.81 million up 295.04% year over year. In the same quarter last year, Calliditas Therapeutics Ab's revenue was $6.28 million.

What was CALT's revenue growth in the past year?

As of Q1 2024, Calliditas Therapeutics Ab's revenue has grown 214.74% year over year. This is 45.44 percentage points higher than the US Biotechnology industry revenue growth rate of 169.3%. Calliditas Therapeutics Ab's revenue in the past year totalled $105.20 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.